Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements (Details Textual)

v3.19.3.a.u2
Note 5 - Fair Value Measurements (Details Textual) - USD ($)
$ in Millions
6 Months Ended
Dec. 31, 2019
Jun. 30, 2019
Jun. 04, 2019
Oct. 31, 2018
Aug. 01, 2018
Jul. 02, 2018
Business Combination, Liabilities Arising from Contingencies, Amount Recognized     $ 14.6      
Exosome Diagnostics, Inc [Member]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 325.0          
Business Combination, Liabilities Arising from Contingencies, Amount Recognized         $ 3.8  
QT Holdings Corporation [Member]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 51.0          
Business Combination, Liabilities Arising from Contingencies, Amount Recognized           $ 5.3
B-MoGen [Member]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 38.0   38.0      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized     $ 5.5      
Embedded Derivative Financial Instruments [Member]            
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 0.8          
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member]            
Derivative, Notional Amount       $ 380.0    
CCXI [Member]            
Investments, Total 11.3 $ 18.8        
CCXI [Member] | Warrant to Purchase Equity Shares [Member]            
Warrants and Rights Outstanding $ 5.6